Image may be NSFW.
Clik here to view.
Titan Pharmaceuticals (NSDQ:TTNP) and Opiant Pharmaceuticals(NSDQ:OPNT) announced this week that the companies are partnering to develop a subcutaneous implant to deliver an opioid antagonist.
The pair said they plan to conduct a feasibility assessment of such an implant using Titan’s ProNeura sustained release technology. The goal of their collaboration is to devise a way to prevent opioid relapse and overdose in people with opioid use disorder, the companies said, by delivering therapeutic levels of an opioid antagonist for six months at a time.
Get the full story at our sister site, Drug Delivery Business News.
The post Titan, Opiant partner to develop subcutaneous implant for opioid use disorder appeared first on MassDevice.
